Anti-Asthmatics And COPD Drugs Market Segmentation – Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies And Combination Drugs

Anti-Asthmatics And COPD Drugs Market Segmentation - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies And Combination Drugs

“Anti-Asthmatics And COPD Drugs Global Market Report 2019”
GlaxoSmithKline Is One Of The Largest Companies In The Anti-Asthmatics And COPD Drugs Market, According To TBRC’s Report
(Companies: Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh and AstraZeneca)

The global anti-asthmatics and COPD drugs market was valued at about $33.4 billion in 2018. North America accounts for the largest share in the global anti-asthmatics and COPD drugs market.

View Complete Report @ https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs. 

Major players in the market are Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh and AstraZeneca. GlaxoSmithKline plc is a British multinational pharmaceutical company headquartered in Brentford, London. 

Request A Sample Of The Global Anti-Asthmatics And COPD Drugs Market Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2417&type=smp

The global anti-asthmatics and COPD drugs market is expected to grow to $42.01 billion at a rate of about 5.9% through 2022. Increasing patent expiration of innovator drugs is restraining the anti-asthmatics and COPD drug market. Due to patent expiration, generic drugs are entering the market which are inexpensive when compared to innovator drugs. For example, the patent for Advair Diskus inhaler by GSK had expired in 2016, and many players including Novartis, Hikama, and Mylan are trying to get FDA approval for a generic version of the innovator drug.

The use of combination drugs for the treatment of asthma and COPD is increasing. This is due to the greater impact on patient reported outcomes (PROs) as compared to with monotherapies. For example, the combination of short acting beta agonists (SABA) and short acting muscarinic antagonists (SAMA) are superior compared to using either medication alone in treatment for improving lung function. The use of combination long acting beta agonists (LABA), and long acting muscarinic antagonists (LAMA) have improved lung function more, as compared to long acting monotherapy bronchodilators.

Few Points From List Of Tables

Table 1: Global Historic Market Growth, 2014-2018, $ Billion
Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
Table 3: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 4: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 5: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 6: Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 7: Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 8: Asia-Pacific, Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 9: Asia-Pacific, Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 10: China, Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 11: China, Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 12: India, Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 13: India, Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Table 14: Japan, Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Order a Copy Of Complete Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2417

About The Business Research Company

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

 

Media Contact
Company Name: The Business Research Company
Contact Person: Nitin
Email: Send Email
Phone: 08897263534
Address:1st Floor, Anshu Colors Building, Road Number 1 Park View Enclave, Jubilee Hills
City: Hyderabad 500033
State: Telengana
Country: India
Website: https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report